Insulet (NASDAQ:PODD) Hits New 52-Week High - What's Next?

Key Points

• Insulet Corporation (NASDAQ:PODD) reached a new 52-week high of $341.14 during trading, currently trading at $338.79.
• Research analysts have a consensus rating of "Moderate Buy" on Insulet stock, with a price target averaging $332.71, indicating strong interest in the company's future performance.
• The company reported $1.17 EPS for its most recent quarter, significantly exceeding analysts' expectations of $0.92, coupled with a 32.9% revenue increase year-over-year.

Insulet Corporation (NASDAQ:PODD - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The stock traded as high as $341.14 and last traded at $338.79, with a volume of 515158 shares changing hands. The stock had previously closed at $337.60.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Wells Fargo & Company raised their target price on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. The Goldman Sachs Group assumed coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Stock Performance

The stock's 50-day moving average price is $307.55 and its 200-day moving average price is $289.86. The company has a market cap of $24.53 billion, a P/E ratio of 105.91, a PEG ratio of 2.92 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Insulet by 0.5% during the second quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier's stock worth $2,735,991,000 after purchasing an additional 39,403 shares during the period. Geode Capital Management LLC lifted its position in Insulet by 3.1% during the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier's stock worth $603,211,000 after purchasing an additional 58,309 shares during the period. American Century Companies Inc. lifted its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares during the period. Groupama Asset Managment lifted its position in Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after purchasing an additional 3,759 shares during the period. Finally, Norges Bank acquired a new position in Insulet during the second quarter worth about $324,689,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.